Dr Lal Pathlabs Ltd
18 Dec 2024 12:00 AM
Dr Lal Pathlabs allots 5,483 equity shares under ESOP,
Dr Lal Pathlabs has allotted 5,483 equity shares under ESOP on 18 December 2024. Pursuant to the above allotment, the Paid-up Equity Share Capital of the Company increased to Rs 83,58,77,350/- divided into 8,35,87,735 equity shares of Rs 10/-each. Powered by Capital Market - Live News
Dr Lal Pathlabs Ltd
05 Dec 2024 12:00 AM
Dr Lal Pathlabs allots 3,000 equity shares under ESOP,
Dr Lal Pathlabs has allotted 3,000 equity shares under ESOP on 05 December 2024. Pursuant to the above allotment, the Paid-up Equity Share Capital of the Company increased to Rs 83,58,22,520/- divided into 8,35,82,252 equity shares of Rs 10/-each.Powered by Capital Market - Live News
Dr Lal Pathlabs Ltd
30 Oct 2024 12:00 AM
Dr. Lal PathLabs allots Equity shares,
Dr. Lal PathLabs approved allotment of 5,000 Equity Shares under the ESOP 2010 Plan of the Company on 30th October 2024 through circular resolution.Powered by Capital Market - Live News
Dr Lal Pathlabs Ltd
23 Oct 2024 12:00 AM
Dr Lal Pathlabs consolidated net profit rises 18.21% in the September 2024 quarter,
Net profit of Dr Lal Pathlabs rose 18.21% to Rs 129.20 crore in the quarter ended September 2024 as against Rs 109.30 crore during the previous quarter ended September 2023. Sales rose 9.80% to Rs 660.20 crore in the quarter ended September 2024 as against Rs 601.30 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales660.20601.30 10 OPM %30.6729.57 - PBDT218.40188.10 16 PBT183.10152.20 20 NP129.20109.30 18 Powered by Capital Market - Live News
Dr Lal Pathlabs Ltd
23 Oct 2024 12:00 AM
Board of Dr. Lal PathLabs recommends Second Interim dividend,
Dr. Lal PathLabs announced that the Board of Directors of the Company at its meeting held on 23 October 2024, inter alia, have recommended the Second Interim dividend of Rs 6 per equity Share (i.e. 60%) , subject to the approval of the shareholders.Powered by Capital Market - Live News
Subscribe for our
newsletter
newsletter